Patents by Inventor Michael B. Gross
Michael B. Gross has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11648227Abstract: This invention relates to methods for treating dry eye and improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands of a mammal, comprising the steps of administering a composition consisting essentially of an effective amount of omega-3 fatty acids on a daily dosage basis to the mammal having inflamed or dysfunctional meibomian glands, wherein the effective amount of omega-3 fatty acids comprises eicosapentaenoic acid (EPA) in an amount greater than 600 mg and in the re-esterified triglyceride form, and wherein the composition administered does not include any additional omega-6 fatty acids beyond the range normally found in the source material of the omega-3 fatty acids. The composition administered may facilitate an increase in levels of anti-inflammatory omega-3's in the meibum composition of the treated meibomian glands of the mammal and a decrease in the levels of inflammatory omega-6's in the meibum composition of the treated meibomian glands.Type: GrantFiled: March 4, 2022Date of Patent: May 16, 2023Assignee: PRN Physician Recommended Nutriceuticals LLCInventors: S. Gregory Smith, Michael B. Gross, Olav E. Sandnes
-
Publication number: 20220184018Abstract: This invention relates to methods for treating dry eye and improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands of a mammal, comprising the steps of administering a composition consisting essentially of an effective amount of omega-3 fatty acids on a daily dosage basis to the mammal having inflamed or dysfunctional meibomian glands, wherein the effective amount of omega-3 fatty acids comprises eicosapentaenoic acid (EPA) in an amount greater than 600 mg and in the re-esterified triglyceride form, and wherein the composition administered does not include any additional omega-6 fatty acids beyond the range normally found in the source material of the omega-3 fatty acids. The composition administered may facilitate an increase in levels of anti-inflammatory omega-3's in the meibum composition of the treated meibomian glands of the mammal and a decrease in the levels of inflammatory omega-6's in the meibum composition of the treated meibomian glands.Type: ApplicationFiled: March 4, 2022Publication date: June 16, 2022Applicant: PRN PHYSICIAN RECOMMENDED NUTRICEUTICALS LLCInventors: S. Gregory Smith, Michael B. Gross, Olav E. Sandnes
-
Patent number: 11077161Abstract: This invention relates to methods for administering an effective amount of a dietary or nutritional supplement composition that effectively changes the levels of biomarkers in the synovium of a joint and resulting in decreased pain and ultimately better outcomes for subjects. The formulation comprises an effective amount of the following: Boswellia; Vitamin C; Ginger; Turmeric; Vitamin D3; and Rutin. In a preferred embodiment of the composition of the invention, the composition is substantially free of omega-3 fatty acids.Type: GrantFiled: March 16, 2018Date of Patent: August 3, 2021Assignee: Orthopedic Solutions LLCInventors: Michael B. Gross, Javad Parvizi
-
Publication number: 20210121430Abstract: This invention relates to methods for treating dry eye and improving the quality of the meibum composition of inflamed or dysfunctional meibomian glands of a mammal, comprising the steps of administering a composition consisting essentially of an effective amount of omega-3 fatty acids on a daily dosage basis to the mammal having inflamed or dysfunctional meibomian glands, wherein the effective amount of omega-3 fatty acids comprises eicosapentaenoic acid (EPA) in an amount greater than 600 mg and in the re-esterified triglyceride form, and wherein the composition administered does not include any additional omega-6 fatty acids beyond the range normally found in the source material of the omega-3 fatty acids. The composition administered may facilitate an increase in levels of anti-inflammatory omega-3?s in the meibum composition of the treated meibomian glands of the mammal and a decrease in the levels of inflammatory omega-6?s in the meibum composition of the treated meibomian glands.Type: ApplicationFiled: October 22, 2020Publication date: April 29, 2021Applicant: PRN Physician Recommended Nutriceuticals, LLCInventors: S. Gregory Smith, Michael B. Gross, Olav E. Sandnes
-
Patent number: 10709680Abstract: This invention relates to methods for improving the quality of the meibum composition of the meibomian glands to enhance or improve the lipid layer of the tear and increase tear breakup time by way of elevating the omega-3 index in patients suffering from symptoms of dry eye, posterior blepharitis, and/or meibomian gland dysfunction. The methods comprise administering a supplementation of omega-3 fatty acids to a patient having an inflamed meibomian gland so as to facilitate an increase in the amount of omega-3's acting as an anti-inflammatory and, respectively, decrease the amount of omega-6's (arachidonic acid) acting as an inflammatory in the composition of the meibum, thereby normalizing the lipid layer of the tear and effectively reducing the associated symptoms. In certain embodiments, the supplementation of omega-3's comprises the esterified or re-esterified triglyceride form.Type: GrantFiled: March 2, 2018Date of Patent: July 14, 2020Inventors: S. Gregory Smith, Michael B. Gross, Olav E. Sandnes
-
Publication number: 20200138897Abstract: This invention relates to methods for administering an effective amount of a dietary or nutritional supplement composition that effectively changes the levels of biomarkers in the synovium of a joint and resulting in decreased pain and ultimately better outcomes for subjects. The formulation comprises an effective amount of the following: Boswellia; Vitamin C; Ginger; Turmeric; Vitamin D3; and Rutin. In a preferred embodiment of the composition of the invention, the composition is substantially free of omega-3 fatty acids.Type: ApplicationFiled: March 16, 2018Publication date: May 7, 2020Inventors: Michael B. Gross, Javad Parvizi
-
Publication number: 20180214407Abstract: This invention relates to methods for improving the quality of the meibum composition of the meibomian glands to enhance or improve the lipid layer of the tear and increase tear breakup time by way of elevating the omega-3 index in patients suffering from symptoms of dry eye, posterior blepharitis, and/or meibomian gland dysfunction. The methods comprise administering a supplementation of omega-3 fatty acids to a patient having an inflamed meibomian gland so as to facilitate an increase in the amount of omega-3's acting as an anti-inflammatory and, respectively, decrease the amount of omega-6's (arachidonic acid) acting as an inflammatory in the composition of the meibum, thereby normalizing the lipid layer of the tear and effectively reducing the associated symptoms. In certain embodiments, the supplementation of omega-3's comprises the esterified or re-esterified triglyceride form.Type: ApplicationFiled: March 2, 2018Publication date: August 2, 2018Inventors: S. Gregory Smith, Michael B. Gross, Olav E. Sandnes
-
Publication number: 20160310456Abstract: This invention relates to compositions for reducing levels of arachidonic acid (omega-6) found at the cellular level in tissue after surgery, wherein the composition consists of an effective amount of at least one fatty acid. In certain embodiments, the composition includes omega-3 fatty acids, which may comprise the triglyceride form. The omega-3 fatty acids of the present invention may comprise eicosapentaenoic acid (EPA) in an amount greater than 600 mg. The omega-3 fatty acids may also comprise docosahexaenoic acid (DHA) in an amount greater than 500 mg. In some embodiments, the composition of the present invention comprises an amount of EPA and an amount of DHA in a 3:1 ratio. Correspondingly, the present invention is further directed to methods for reducing inflammation in tissue after surgery.Type: ApplicationFiled: June 29, 2016Publication date: October 27, 2016Inventors: S. Gregory Smith, Michael B. Gross
-
Patent number: 9381183Abstract: This invention relates to methods for improving changing the quality of the meibum composition of the meibomian glands to enhance or improve the lipid layer of the tear and increase tear breakup time by way of elevating the omega-3 index in patients suffering from symptoms of dry eye, posterior blepharitis, and/or meibomian gland dysfunction. The methods comprise administering a supplementation of omega-3 fatty acids to a patient having an inflamed meibomian gland so as to facilitate an increase in the amount of omega-3's acting as an anti-inflammatory and, respectively, decrease the amount of omega-6's (arachidonic acid) acting as an inflammatory in the composition of the meibum, thereby normalizing the lipid layer of the tear and effectively reducing the associated symptoms. In certain embodiments, the supplementation of omega-3's comprises the esterified or re-esterified triglyceride form.Type: GrantFiled: March 12, 2013Date of Patent: July 5, 2016Assignee: Physicians Recommended Nutriceuticals, LLCInventors: S. Gregory Smith, Michael B. Gross, Olav E. Sandnes
-
Patent number: 9115078Abstract: This invention relates to methods for administering an effective amount of a dietary or nutritional supplement composition that effectively changes the quality of the meibum lipid composition of inflamed or dysfunctional meibomian glands so as to improve or increase tear break up time, reduce tear osmolarity, and elevate the omega-3 index, while reducing or eliminating the symptoms associated with dry eye or meibomianitis. The dietary or nutritional supplement composition administered to the patient suffering from inflamed or dysfunctional meibomian glands comprises an effective amount of omega-3 fatty acids.Type: GrantFiled: July 18, 2012Date of Patent: August 25, 2015Assignee: Physicians Recommended Nutriceuticals, LLCInventors: S. Gregory Smith, Michael B. Gross, Olav E. Sandnes
-
Publication number: 20140024625Abstract: This invention relates to methods for improving changing the quality of the meibum composition of the meibomian glands to enhance or improve the lipid layer of the tear and increase tear breakup time by way of elevating the omega-3 index in patients suffering from symptoms of dry eye, posterior blepharitis, and/or meibomian gland dysfunction. The methods comprise administering a supplementation of omega-3 fatty acids to a patient having an inflamed meibomian gland so as to facilitate an increase in the amount of omega-3's acting as an anti-inflammatory and, respectively, decrease the amount of omega-6?s (arachidonic acid) acting as an inflammatory in the composition of the meibum, thereby normalizing the lipid layer of the tear and effectively reducing the associated symptoms. In certain embodiments, the supplementation of omega-3's comprises the esterified or re-esterified triglyceride form.Type: ApplicationFiled: March 12, 2013Publication date: January 23, 2014Inventors: S. Gregory Smith, Michael B. Gross, Olav E. Sandnes
-
Publication number: 20130065867Abstract: This invention relates to methods for administering an effective amount of a dietary or nutritional supplement composition that effectively changes the quality of the meibum lipid composition of inflamed or dysfunctional meibomian glands so as to improve or increase tear break up time, reduce tear osmolarity, and elevate the omega-3 index, while reducing or eliminating the symptoms associated with dry eye or meibomianitis. The dietary or nutritional supplement composition administered to the patient suffering from inflamed or dysfunctional meibomian glands comprises an effective amount of omega-3 fatty acids.Type: ApplicationFiled: July 18, 2012Publication date: March 14, 2013Inventors: S. Gregory Smith, Michael B. Gross, Olav E. Sandnes